Defining the clinical response to 17-alpha hydroxyprogesterone caproate - 25/01/19
Doi : 10.1016/j.ajog.2018.08.040
Steve N. Caritis, MD 
, Alisse Hauspurg, MD
, Alisse Hauspurg, MD Departments of Obstetrics, Gynecology, and Reproductive Sciences, Division of Maternal-Fetal Medicine, University of Pittsburgh, 300 Halket Street, Pittsburgh, PA 15213
Magee Womens Hospital, University of Pittsburgh, 300 Halket Street, Pittsburgh, PA 15213
Raman Venkataramanan, PhD
Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, 15213
Lara Lemon, PhD, PharmD
Department of Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA 15213
Le texte complet de cet article est disponible en PDF.
Plan
| The views expressed herein are those of the authors and do not represent the views of the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the Maternal-Fetal Medicine Units Network, or the National Institutes of Health. |
|
| Support for this specific project was not necessary because this was an observational study of already published data. The initial randomized controlled trial was funded by the Maternal-Fetal Medicine Networks Unit (grant HD021410). Additional funding was provided by the Obstetric-Fetal Pharmacology Research Center under award number HD047905. |
|
| The authors report no conflict of interest. |
© 2018
Publié par Elsevier Masson SAS.
Vol 219 - N° 6
P. 623-625 - décembre 2018 Retour au numéro
Article précédent
- Uterine and cervical cancer with irreducible pelvic organ prolapse
- Christopher P. Chung, Stephen J. Lee, Mark T. Wakabayashi
- Female pelvic medicine and reconstructive surgery fellows’ exposure to transgender health care
- Olivia H. Chang, Miriam J. Haviland, Emily Von Bargen, Yvonne Gomez-Carrion, Michele R. Hacker, Janet Li
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?